Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.60 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | CCR3 | P51677 | 2/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888729 | 0.86 | HTR7 (0.63) | CCR3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7247797 | 0.85 | CARM1 (0.56) | CARM1PRMT6HTR2ACCR3CHRNB4 | |
| SCHEMBL7248608 | 0.80 | CARM1 (0.64) | CARM1PRMT6HTR2ACCR3CHRNB4 | |
| SCHEMBL12040805 | 0.79 | KCNH2 (0.71) | CARM1PRMT6CCR3BCHE | |
| SCHEMBL7251644 | 0.79 | CARM1 (0.62) | CARM1PRMT6HTR2ACCR3CHRNB4 | |
| SCHEMBL1787933 | 0.79 | CHRNB2 (0.50) | CARM1PRMT6CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL12041254 | 0.78 | CARM1 (0.64) | CARM1PRMT6HTR2ACCR3BCHE | |
| Bromide SCHEMBL7250389 | 0.78 | SIGMAR1 (0.68) | CARM1PRMT6CCR3BCHE | |
| SCHEMBL12041337 | 0.77 | CARM1 (0.63) | CARM1PRMT6CCR3BCHE | |
| SCHEMBL12041275 | 0.77 | KCNH2 (0.64) | CARM1PRMT6CCR3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | CARM1 1889/4885PRMT6 3340/4885HTR2A 157/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | CARM1 1889/4885PRMT6 3340/4885HTR2A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.